A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Study sponsor: UroGen Pharma Ltd. · URGN
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-04-26Actual
Enrollment · participants240Actual
Source updated2026-05-11Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.